SAN DIEGO, Nov. 10 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that Mike Dudley, Pharm.D. has joined the company as Vice President of Drug Development. Dr. Dudley will be an integral part of Mpex’s executive management team and will be responsible for the preclinical development and clinical pharmacology of Mpex’s anti-bacterial drug candidates.
“We’re delighted Mike has joined our company,” said Bill Gerhart, President and CEO, Mpex Pharmaceuticals. “We are assembling a world-class management team skilled at developing novel anti-bacterial drug products, and Mike is a very important addition to that team.”
Dudley brings to Mpex a highly relevant background of experience in both industry and academic research. Prior to joining Mpex pharmaceuticals he was the Vice President, Preclinical and Clinical Sciences at Diversa Corporation where he was responsible for all aspects of an antifungal development program, and the development of an internal preclinical scientific department to support discovery and preclinical programs. Prior to Diversa, he spent six years at Microcide where he became the Vice President, Pharmacology and Microbiology. His responsibilities at Microcide included oversight of all discovery drug evaluation, preclinical, and clinical pharmacology of novel anti-infectives. Prior to Microcide, Dudley served as a professor and led academic research programs at the University of Rhode Island and Brown University in non-clinical and clinical (Phases I-IV) investigations for several classes of anti-bacterial and anti-viral agents that are currently in clinical use. He has also served as a consultant to the pharmaceutical industry, the US FDA, and currently serves on the Antimicrobial Susceptibility Testing Subcommittee of the Clinical Laboratory Standards Institute (formerly known as NCCLS).
About Mpex Pharmaceuticals:
Mpex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. Resistance to multiple antibiotics has resulted in unacceptably high morbidity and mortality rates that costs the U.S. healthcare system $5 billion annually and kills more than 90,000 Americans each year. Despite the efforts of drug development companies, new antibiotics have failed to significantly improve these worsening statistics. To address this medical need, Mpex is developing inhibitors of bacterial resistance that can be combined with proven antibiotics to significantly increase their potency against resistant bacteria. For more information: www.mpexpharma.com
Mpex Pharmaceuticals is a registered trademark of Mpex Pharmaceuticals, Inc. All other product and company names may be registered trademark or trademarks of their respective owners.
Mpex Pharmaceuticals, Inc.
CONTACT: Neil Berkley of Mpex Pharmaceuticals, Inc., +1-858-875-2840, ext.223, nlberkley@mpexpharma.com; or Jennifer Larson of WeissComm Partners,+1-415-946-1074, jlarson@weisscommpartners.com, for Mpex Pharmaceuticals,Inc.
Web site: http://www.mpexpharma.com//
